Oral 5-Aminosalicylate, Mesalamine Suppository, and Mesalamine Enema as Initial Therapy for Ulcerative Proctitis in Clinical Practice with Quality of Care Implications

Table 4

Cumulative incidence of hospitalization for inflammatory bowel disease, by treatment group and duration of follow-up.

Treatment group	Month 3; (%)	Month 6; (%)	Month 9; (%)	Month 12; (%)
Oral 5-ASA )	3 (2.2)	4 (2.9)	4 (2.9)	5 (3.6)
Mesalamine suppository ()	4 (1.2)	5 (1.5)	5 (1.5)	6 (1.8)
Mesalamine enema ()	1 (1.2)	1 (1.2)	2 (2.4)	2 (2.4)

Oral 5-ASA: oral 5-aminosalicylate.